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Abstract  
        
Literature data are reviewed on the properties of acetaminophen (paracetamol) related to the 
biopharmaceutics classification system (BCS). According to the current BCS criteria, 
acetaminophen is BCS Class III compound. Differences in composition seldom, if ever, have 
an effect on the extent of absorption. However, some studies show differences in rate of 
absorption between brands and formulations. In particular, sodium bicarbonate, present in 
some drug products, was reported to give an increase in the rate of absorption, probably 
caused by an effect on gastric emptying. In view of Marketing Authorizations (MAs) given in a 
number of countries to acetaminophen drug products with rapid onset of action, it is 
concluded that differences in rate of absorption were considered therapeutically not relevant 
by the Health Authorities. Moreover, in view of its therapeutic use, its wide therapeutic index 
and its uncomplicated pharmacokinetic properties, in vitro dissolution data collected according 
to the relevant Guidances can be safely used for declaring bioequivalence (BE) of two 
acetaminophen formulations. Therefore, accepting a biowaiver for immediate release (IR) 
acetaminophen solid oral drug products is considered scientifically justified, if the test product 
contains only those excipients reported in this paper in their usual amounts and the test 
product is rapidly dissolving, as well as the test product fulfils the criterion of similarity of 
dissolution profiles to the reference product.  
 
INTRODUCTION 
 
A monograph based on literature data is presented on acetaminophen, also widely known as 
paracetamol, with respect to its biopharmaceutical properties and the risk of waiving in vivo 
bioequivalence (BE) testing for the approval of new and/or reformulated immediate release 
(IR) solid oral dosage forms. The purpose and scope of these monographs has been 
discussed previously.[1] Briefly, the aim of the present study is to evaluate all pertinent data 
available from literature sources to assess the appropriateness of such a biowaiver from the 
biopharmaceutical point of view and also from the perspective of public health. Monographs 
have been published on atenolol,[1] chloroquine,[2] propranolol,[1] ranititine,[3] and 
verapamil.[1] 
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EXPERIMENTAL 
        
Published information was obtained from PubMed, up to 08/2004 and through the 
International Pharmaceutical Abstracts. Key words used were: paracetamol, acetaminophen, 
indication, solubility, polymorphism, partition coefficient, dose, permeability, stereospecificity, 
absorption, distribution, metabolism, excretion, and dissolution. No other selection criteria 
were used. 
 
GENERAL CHARACTERISTICS 
 
Acetaminophen has INN name: paracetamol. Its chemical name is N-(4-hydroxyphenyl) 
acetamide. Its structure is shown in Figure 1.  
 
 
 
Figure 1. Structure of acetaminophen. 
 
Therapeutic Indication and Therapeutic Index 
Acetaminophen has analgesic and antipyretic properties and weak anti-inflammatory activity 
and is used in the symptomatic management of moderate pain and fever.[4] When taken at 
recommended doses it has an excellent safety profile, notably lacking the gastrointestinal (GI) 
side effects of aspirin and ibuprofen.[5] 
 
However, acute overdosage with acetaminophen, whether accidental or deliberate, is 
relatively common and can be extremely serious. Ingestion of 10-15 g of acetaminophen by 
adults may cause severe hepatocellular necrosis and doses of 20-25 g are potentially 
fatal.[4],[6] 
 
CHEMICAL PROPERTIES 
        
Polymorphism 
Three metastable forms of acetaminophen are known.[7-12] Orthorhombic acetaminophen is 
suitable for direct compression tableting and may also be slightly more soluble[13] but has 
been crystallized only in small quantities and the only commercially available form is 
monoclinic acetaminophen, the thermodynamically most stable modification.[14] 
 
Solubility 
One part of acetaminophen is soluble in 70 parts of water at room temperature[15],[16] and 
soluble 1 in 20 parts in boiling water.[4],[15] Other sources report an aqueous solubility of 
14.7 mg/mL at 20°C,[17] 14.3 mg/mL at 25°C,[18] and 23.7 mg/mL at 37°C.[17] 
 
Partition Coefficient 
A logP (n-octanol/water) value of 0.2 has been measured.[19] Calculations using 
fragmentation methods based on atomic contributions to lipophilicity and by using the ClogP 
program (version 3.0, Biobyte Corp., Claremont, CA) gave values of 0.31(log P),[20] 
0.49(ClogP),[21] and 0.89(log P).[21] 
 
pKa 
An acidic pKa of 9.5 at 25°C is reported.[16],[22] 
 
Dose and Dosage Forms Strengths 
The WHO recommended dose is 100-500 mg.[23] The optimum single dose for adults is 1 
g.[24] Acetaminophen drug products with a marketing authorization (MA) are conventional IR 
tablets and capsules. However, MAs have been also given to granulates,[4],[25-27] 
effervescent tablets,[4],[25-27] and syrups.[4],[25-28] Drug products containing 
acetaminophen in combination with other active pharmaceutical ingredients (APIs) can have a 
MA.[4],[25-28] However, this monograph pertains to conventional IR solid oral dosage forms 
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containing acetaminophen as the sole API. Such formulations contain 500 mg per tablet.[25-
28] 
 
PHARMACOKINETIC PROPERTIES 
 
Absorption and Bioavailability 
The absolute bioavailability (BA) in the fasted state was reported in the range 62%-89%.[29-
32] The incomplete absolute BA is caused by a presystemic clearance of about 20% of an 
oral dose.[31-34] Peak plasma concentrations are reached within 0.17-1.2 h 
postdosing.[29],[35-43] The oral absolute BA was reported not to vary with the dose in range 
between 5 and 20 mg/kg,[31] but other authors reported AUC values and peak plasma 
concentrations to be dose-dependent at doses between 325 and 2000 mg.[43] Food reduces 
the absorption of acetaminophen tablets by increasing tmax and decreasing Cmax 
values.[44],[45] Food effect is primarily due to delays in gastric emptying.[46] Although there 
are no direct published data on the absolute BA in the fed state, food does not affect the total 
amount of acetaminophen reaching the blood.[44],[45] 
 
Permeability 
Stewart et al.[47] using a single-pass intestinal rat perfusion technique, measured the wall 
permeability, Pw, for acetaminophen to be 0.86 ± 0.5 × 10-4 cm/s and they estimated the 
fraction absorbed to be 80%. Using rat perfusions, Lu et al.[48] estimated the dimensionless 
wall permeability, , of acetaminophen 0.6 ± 0.2 whereas using the chronically isolated rat 
jejunal loop model they estimated the dimensionless effective wall permeability  of 0.9 ± 0.1. 
From acetaminophen's diffusivity value (6.86 × 10-4 cm2/min)[47] and assuming 0.2 cm for 
the radius of rat intestine, the wall permeability and the effective wall permeability in the rat 
can be calculated for the corresponding dimensionless numbers to be 0.34 and 0.54 × 10-4 
cm/s, by using the relationship Pw = Pw*(D/R)[Note a], where D is the solute aqueous 
diffusivity and R is the radius of the intestine.[49] Recently, using the Ussing chamber, the 
permeability of acetaminophen through the rat jejunal wall was measured to be 0.09 × 10-4 
cm/s.[50] This value is much lower than the values estimated from intestinal perfusion. 
However, the Ussing chamber technique leads to Pw values that are often lower than the 
values estimated from intestinal perfusions.[51] 
 
Distribution 
The apparent volume of distribution of acetaminophen is reported to be 0.69-1.36 
L/kg.[22],[35],[52-56] Plasma protein binding is 20%-25% at usual therapeutic 
concentrations.[41],[56],[57] After overdosage, 20%-50% of the drug may be bound to 
proteins.[58] Binding to red blood cells is reported to be 10%-20%.[56] Acetaminophen 
crosses the placenta and is present in breast milk[56] with an average milk/plasma 
concentration ratio of about 1.24.[59] Of the acetaminophen present in breast milk, 85% is 
bound to milk proteins.[60] 
 
Metabolism and Excretion 
Acetaminophen is metabolized by microsomal enzymes in the liver, with 85%-90% of the drug 
undergoing glucuronidation and sulfation to inactive metabolites that are eliminated in the 
urine. A smaller amount is conjugated with cysteine and mercapturic acid and only 5% of the 
drug is eliminated unchanged in the urine.[61] Total urinary recovery of acetaminophen in 24 
h is reported to be 71.5%-95%, as free and/or conjugated.[56],[62-64] The clearance ranges 
between 11.8 and 22.3 L/h[32],[35],[36],[53],[62],[65],[66] and the total plasma clearance of 
acetaminophen has been reported to show a 12% difference after 20 and 5 mg/kg doses.[31] 
The elimination half life is reported to be between 1.9 and 4.3 h.[22],[32],[53],[54],[56],[62] 
 
DOSAGE FORM PERFORMANCE 
        
Excipients and/or Manufacturing Variations 
The relative BA of acetaminophen from solid dosage forms has been studied frequently. Most 
studies were carried out in humans, but two animal studies have been also reported. In 
rabbits, no significant differences in Cmax and AUC0   were found between rapidly 
disintegrating tablets and conventional tablets.[67] In dogs, no significant differences were 
found between two conventional tablets.[68] 
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Studies in humans in general show similar results. While most studies report no difference in 
extent of absorption, differences in rate of absorption between drug products were sometimes 
found. In one of the earliest relevant studies, Sotiropoulus et al.[69] evaluated three tablets 
and one liquid acetaminophen product for their comparative BA, reporting a BA relative to the 
liquid dosage form of 82%, 87%, and 92%, respectively. However, based on urinary excretion 
data, these differences were not statistically significant and only the amount excreted from 0 
to 4 h varied with the formulation. Hekimoglu et al.[70] evaluated the BA of three brands of 
acetaminophen tablets in comparison to a solution. BAs of the brands relative to the solution 
were 98%, 95% and 99%, respectively, with differences being not statistically significant. 
However, the amount excreted during the first hour varied among the formulations. Walter-
Sack et al.[71] compared a solid and a liquid oral dosage forms that did not show differences 
in the AUC0-12 h and in Cmax. An evaluation of four brands of acetaminophen tablets by 
Hekimoglu et al.[72] did not display statistically significant differences in BA, but differences in 
the urinary excretion during the first hours, reflecting differences in rate of absorption, were 
observed. Retaco et al.[73] studied the BA of two lots of paracetamol tablets and although the 
total amount excreted in urine was similar between the two formulations, differences were 
found during the early stages of the absorption process. Dominguez et al.[74] using urinary 
excretion data, reported nonsignificant differences in the rates and relative BA's ranging from 
94% to 131% of three commercial formulations versus the innovator. Bababola et al.[75] 
reported a study of two commercial brands versus the innovator. While the absorption rate of 
one brand, as indicated by tmax, was significantly shorter than those of the innovator, the 
extent of absorption, as indicated by AUC, was comparable among the three brands. Sevilla-
Tirado et al.[76] compared three tablets, one effervescent tablet, and a powder sachet, and 
found that the extent of absorption, expressed as AUC0  , did not exhibit differences between 
formulations. However, for the rate of absorption, expressed as Cmax and partial AUC 
values, differences were observed; two tablets had a rate of absorption as fast as the 
effervescent tablet, but the other tablet, being the innovator, had a somewhat slower 
absorption rate.[76] 
 
Of special interest are recently introduced acetaminophen products containing large amounts 
of sodium bicarbonate. Such dosage forms are claimed to have fast drug absorption. Grattan 
et al.[37] compared the pharmacokinetics of one commercially available acetaminophen tablet 
and one soluble commercially available acetaminophen tablet with two development tablet 
formulations, one containing 400 mg sodium bicarbonate and the other containing 630 mg 
sodium bicarbonate. The results demonstrated that addition of 630 mg sodium bicarbonate 
increased the rate of absorption of acetaminophen relative to both the conventional tablets 
and the soluble tablets, as indicated by a shorter tmax and higher Cmax, whereas the 
addition of 400 mg sodium bicarbonate increased the absorption rate of acetaminophen 
relative to conventional acetaminophen tablets only. These findings were recently confirmed 
by Kelly et al.[77] who compared an acetaminophen tablet containing 630 mg sodium 
bicarbonate with a conventional tablet. The rate of absorption, indicated by t50% and t90%, 
was about twice as fast compared to the conventional tablets, both in the fasted state and the 
fed state. It was suggested that a combination of faster disintegration and gastric emptying of 
the tablets containing sodium bicarbonate is responsible for the faster rate of absorption. The 
differences in gastric emptying were thought to be more pronounced in the fasted state and 
the differences in disintegration more pronounced in the fed state.[77] The data of Grattan et 
al. and Kelly et al. are supported by earlier reports that effervescent tablets show faster 
absorption characteristics than conventional solid tablets.[76],[78] 
 
The excipients used in IR solid oral dosage forms having a MA in Germany (DE), Finland (FI), 
Greece (GR), and The Netherlands (NL) are shown in Table 1. In previous monographs, MAs 
of solid oral dosage forms were taken as indicators that these drug products had successfully 
passed an in vivo BE test.[1] However, for acetaminophen, this cannot be assumed. The 
bioavailability committee of the regulatory authorities of DE classified acetaminophen in 1998 
as an API for which in vivo BE testing was not required.[79] Also in NL, acetaminophen is on 
such a list.[80] The DE list was recently withdrawn, but the MA granted under that provision 
remained in place.[81]  
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Table 1. Excipientsa Present in Acetaminophenb IR Solid Oral Drug Productsc with a 
Marketing Authorization (MA) in Germany (DE), Finland (FI), Greece (GR), and The 
Netherlands (NL) 
 
Carnauba wax FI (1), NL (2) 
Cellulose DE (3-13), FI (1, 14-16), GR (17), NL (2, 18-27) 
Croscarmellose NL (21) 
Croscarmellose sodium DE (4, 8, 11), FI (15), GR (28), NL (29-31) 
Crospovidone DE (3, 10, 32), NL (27) 
Ethyl parahydroxybenzoate NL (33) 
Gelatin DE (3, 34), FI (14), NL (29-31) 
Glyceryl palmitostearate NL (24) 
Hydroxypropylcellulose DE (35), GR (36), NL (19, 23, 27) 
Hypromellose FI (1, 37-39), GR (17), NL (2, 21, 40, 41) 
Lactose NL (22) 
Macrogol FI (1), NL (2, 21) 
Magnesium stearate DE (3, 4, 6-8, 10, 11, 13, 42), FI (1, 14-16, 37), GR (17, 43), NL (2, 19, 21-23, 25-27, 29-
31, 33) 
Maize starch DE (4, 6-11, 13, 42, 44, 45), FI (1, 15, 38, 39, 46), GR (28, 36, 43), NL (2, 18, 20-22, 27, 
29-31, 33, 40, 41, 47-52) 
Maize starch, 
pregelatinised 
DE (32), NL (2, 22, 47) 
Methyl 
parahydroxybenzoate 
NL (33) 
Polydextrose FI (1), NL (2) 
Potassium sorbate DE (42), FI (1, 38, 39), GR (36, 43), NL (2, 40, 41) 
Potato starch FI (37), NL (24, 33) 
Potato starch, modified NL (23) 
Povidone DE (4-8, 11-13, 21, 32, 44, 53), FI (1, 15, 16, 37-39, 46), GR (28,36), NL (2, 24, 25, 33, 
40, 41, 48-52) 
Propyl 
parahydroxybenzoate 
NL (33) 
Propylene glycol FI (37) 
Silica DE (3-11, 42, 44, 45), FI (14, 15, 46), GR (43), NL (18-20, 23, 27) 
Sodium cyclamate NL (24) 
Sodium hydrogen 
carbonate 
FI (1), NL (2) 
Sodium lauryl sulfate NL (29) 
Sodium starch glycolate DE (5, 9,44, 45, 53), FI (14, 16, 46), GR (17), NL (18-20, 22, 24-26, 48-52) 
Sodium stearate NL (18, 20) 
Starch, pregelatinised FI (1, 16, 38, 39), NL (26, 41) 
Starch, soluble NL (40) 
Stearic acid DE (5-7, 9, 10, 35, 44, 45, 53), FI (16, 38, 39, 46), GR (28, 36), NL (33, 40, 41, 47-52) 
Stearic palmitic acid DE (12, 32) 
Talc DE (3, 4, 8, 11, 34, 44), FI (14, 15, 37-39, 46), GR (17, 36), NL (21, 33, 40, 41) 
Triacetin FI (1, 38, 39), GR (36), NL (2, 40, 41) 
 
 
  
 
   1, Panadol Zapp 500 mg tabletti, kalvopäällysteinen; 2, Panadol Zapp, filmomhulde 
tabletten 500 mg; 3, Captin® Tabletten 500 mg; 4, Fensum® 500 Tabletten; 5, Mono 
Praecimed® Tabletten; 6, Paracetamol 500-1 A Pharma Tabletten; 7, Paracetamol 500 
HEXAL® bei Fieber und Schmerzen Tabletten; 8, Paracetamol 500 von ct Tabletten; 9, 
Paracetamol BC 500 mg Tabletten; 10, Paracetamol beta® 500 Tabletten; 11, Paracetamol-
ratiopharm® 500 Tabletten 12, Paracetamol Tabletten Lichtenstein; 13, Sinpro® N Tabletten; 
14, Para-Tabs 500 mg tabletti; 15, Paracetamol-ratiopharm 500 mg tabletti; 16, PARAMAX 
Rap 500 mg tabletti; 17, Apotel Uni-Pharma filmcoated tablets 500 mg; 18, Pijnstillende en 
koortsverlagende paracetamol-tabletten 500 mg Samenwerkende Apothekers, tabletten; 19, 
Pijnstillende en koortsverlagende paracetamol tabletten 160 mg/250 mg Samenwerkende 
Apothekers, tabletten; 20, Paracetamol 500 mg Therapeuticon, tabletten; 21, Democyl 500, 
omhulde tabletten 500 mg; 22, Paracetamol 500 PCH, tabletten 500 mg (MA number: 50480); 
23, Paracetamol 500 PCH, tabletten 500 mg (MA number: 50954; 24, Kinderparacetamol CF 
100 mg, tabletten; 25, Paracetamol CF 500 mg, tabletten; 26, Paracetamol, tabletten 500 mg 
(MA holder: Imgroma); 27, Paracetamol Sandoz 500, tabletten 500 mg; 28, Depon Bristol, 
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Squibb tab 500 mg; 29, Momentum, capsules 500 mg; 30, Paracetamol 500 mg, tabletten 
(MA holder: KATWIJK FARMA); 31, Paracetamol 500 mg Katwijk, tabletten; 32, Paracetamol 
Sandoz® 500 mg Tabletten; 33, Paracetamol 500, tabletten 500 mg (MA holder: H. Ten 
Herkel); 34, Ben-u-ron® Kapseln; 35, Enelfa® Tabletten; 36, Panadol Sterling tab 500 mg; 37, 
PAMOL® 500 mg, kalvopäällysteinen tabletti; 38, Panadol 500 mg tabletti, kalvopäällysteinen; 
39, Panadol Forte 1g tabletti, kalvopäällysteinen; 40, Panadol Gladde Tablet, tabletten 500 
mg; 41, Panadol 1000 mg Artrose, omhulde tabletten; 42, Paracetamol STADA® 500 mg 
Tabletten; 43, Apotel Uni-Pharma tab 500 mg; 44, Benuron® Tabletten; 45, Paedialgon® 
Tabletten; 46, Paraceon® 500 mg tabletit; 47, Paracetamol Alpharma 500 mg, tabletten; 48, 
Paracetamol FLX 500 mg, tabletten; 49, Paracetamol 500 mg, tabletten (MA holder: GENRX); 
50, Paracetamol 500 mg, tabletten (MA holder: HEALTHYPHARM); 51, Paracetamol CF 500 
mg, tabletten; 52, Paracetamol 500 mg, tabletten (MA holder: Delphi Pharmaceuticals); 53, 
Paracetamol AL 500 Tabletten. 
  a Printing ink, colorants and flavors are not included. 
  b Drug products containing other drug substances than acetaminophen are excluded. 
  c Excluded are dosage forms that are swallowed by the patient in liquid form: effervescent 
tablets, orodispersible tablets, dispersible tablets, oral powders and granulates, oral 
suspension, oral solution, and powders for oral solution. Chewable tablets are also excluded. 
  
The NL list is still valid for national applications.[80] It is also possible that FI and GR have 
granted MAs without requiring in vivo BE studies. So, these MAs not necessarily indicate that 
in vivo BE studies among these drug products have been conducted. Differences in rate of 
absorption between the different acetaminophen drug products are tolerated by regulatory 
authorities, as can be derived from the MA's granted to acetaminophen syrups and 
effervescent tablets, showing faster absorption than conventional solid dosage forms. 
 
Dissolution and In Vitro-In Vivo Correlation 
The USP 26 specification for acetaminophen tablets is not less than 80% (Q) of the labeled 
amount dissolved in 30 min in 900 mL pH 5.8 phosphate buffer using the paddle apparatus 
operated at 50 rpm.[82] 
 
To the best of our knowledge there are only three reports that claim some kind of correlation 
of in vitro dissolution data with in vivo data. Sotiropoulus et al.[69] found that the rate and 
amount of acetaminophen excreted may be related to the in vitro dissolution rate in 0.1 N 
HCL, using the rotating basket apparatus at 85 rpm. The T50% values for in vitro dissolution 
were 50 min for a generic tablet and 1 min for Tylenol® and Datril®, respectively, whereas the 
relative BAs with respect to acetaminophen powder were 82%, 87%, and 92%, for the generic 
tablet, Tylenol® and Datril®, respectively, showing that the in vitro dissolution rates needed to 
be vastly different to predict differences in relative BAs. Dominguez et al.[74] established a 
weak correlation between mean dissolution time and mean residence time. In vitro dissolution 
data in Dominguez et al.[74] study were obtained in phosphate buffer pH 5.8 using the 
rotating paddle apparatus at 50 rpm. 
 
Rostami-Hodjegan et al.[83] using the USP dissolution method with medium pH 5.8, but at a 
stirring speed of 30 rpm instead of 50 rpm, established a level A correlation between the 
percentage dissolved in vitro and percentage absorbed in vivo. The authors explained this 
correlation from the low stirring speed, by which the in vitro dissolution kinetics under that 
condition was supposed to resemble the population gastric emptying kinetics in vivo. 
 
In contrast, there are many reports showing no correlation between in vitro dissolution and in 
vivo data. Bababola et al.[75] has suggested that the systemic absorption of acetaminophen 
might not be dissolution rate limited and hence using in vitro dissolution rate studies alone to 
establish BE of acetaminophen tablets should be done with caution.[75] This is supported by 
the study of Retaco et al., in which in vivo BE was observed despite differences in in vitro 
dissolution, carried out in phosphate buffer pH 5.8 and in HCl 0.1 N in the paddle apparatus 
operated at 50 rpm.[73] Similar results were observed in the study of Hekimoglu et al., where 
a comparison of the dissolution data obtained in phosphate buffer pH 5.8, at 50 rpm, using 
the paddle apparatus, from three brands of acetaminophen tablets, did show differences in in 
vitro dissolution although their BA's relative to a solution were close to 100% for all brands. 
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Moreover, a series of studies show that different acetaminophen formulations meeting USP 
dissolution criteria were all bioequivalent.[37],[44],[72],[83] 
 
In vivo dissolution of IR tablets in media simulating the contents of the GI lumen in the fasting 
state is usually rapid.[68],[84],[85] The same is true in media simulating the fed state 
conditions in the small intestine.[68],[84] Although in the fed stomach[77] or under conditions 
that simulate the fed intragastric conditions[68],[84],[85] dissolution can be significantly 
retarded, data in humans[77] and in dogs[68] suggest that at least the products that are 
currently in the European market are unlikely to show dissolution dependent rate in 
absorption in the fed state because the gastric emptying limits the absorption kinetics.[68],[77] 
 
Although delayed in vivo dissolution has been observed in the fed state[71],[77] and this has 
been reported to affect blood levels,[71] products that are currently in the European market 
are unlikely to show dissolution dependent BA.[68],[77] 
 
DISCUSSION 
 
Solubility 
Acetaminophen is not substantially ionized at pH less than 9 and, therefore, its solubility does 
not vary with the pH. For the highest strength, i.e., 500 mg, the dose to solubility ratio is 21 
mL, taken the value of 23.7 mg/mL at 37°C for the solubility. This value is less than 250 mL, 
the cut-off limit for an API to be highly soluble as defined by the present BCS 
Guidances.[86],[87] 
 
Permeability 
To date, permeability data for acetaminophen have been collected with rat perfusions and/or 
using the Ussing chamber only. Although internal standards were not used, these data 
suggest that acetaminophen should be classified as low permeability compound because wall 
permeability is less than the generally considered borderline value of 2-4 × 10-4 cm/s.[88] 
More important is the fraction dose absorbed in humans, which is the basis of the 
permeability classification in the present BCS Guidances.[86],[87] The percent of dose 
absorbed can be estimated by adding the percent biotransformed during first-pass from the 
liver to the absolute BA. This suggests that the fraction of dose absorbed is higher than 80%. 
The cut-off limit for an API to be classified as highly permeable by the present BCS 
Guidances[86],[87] is a fraction of dose absorbed to be higher than 90%. 
 
These data lead to classifying acetaminophen as low permeable, although on the borderline. 
Classifying acetaminophen as low permeable has also been suggested by others.[21],[89] 
Intestinal metabolism, i.e., glucuronidation and/or sulfation, after administration, will occur to 
the test product as much as to the reference product. In in vivo BE studies, the data are 
always collected on a crossover basis, so, these effects of intestinal metabolism cancel each 
other out. 
 
Surrogate Techniques for In Vivo Bioequivalence Testing 
Only in vitro dissolution has been used as a surrogate technique to detect in vivo 
bioinequivalence up to now. For an API that is on the borderline between BCS Class I and III, 
in vitro dissolution can be expected to be over-discriminatory, detecting differences in in vitro 
dissolution between products that are actually in vivo bioequivalent. Also, in vivo-in vitro 
correlations are not expected. Most experimental results confirm these expectations, although 
few workers have found limited correlations, as reported above. The important question is 
whether in vitro dissolution is able to detect bioinequivalent products and if so, then by which 
method. Only one report claimed that the USP test at pH 5.8 was inadequate to detect in vivo 
bioinequivalence.[74] However, in this study bioinequivalence was declared on the basis of 
urinary excretion data, using the wider confidence intervals without showing the power of the 
statistical analysis. 
 
Risks for Bioinequivalence Caused by Excipients and/or Manufacturing Parameters 
As discussed above, literature suggests BE of acetaminophen products with respect to extent 
of absorption. However, absorption rate, differences between brands and test formulations 
have been observed, as in the case of tablets containing high amounts of sodium 
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bicarbonate. It was suggested that these differences were caused by differences in 
disintegration and/or gastric emptying rates. Although data in humans are lacking, data in 
rabbits suggest that high concentrations of osmotically active excipients such as mannitol 
may have an impact on the tmax of acetaminophen.[67] 
 
Patient's Risks Associated with Bioinequivalence 
When considering a biowaiver for a drug substance, its therapeutic use and therapeutic index 
also needs to be taken into account.[86],[87] The therapeutic indications of acetaminophen 
are not critical and there is a wide difference between the usual therapeutic dose and toxic 
doses. So it can be assumed that acetaminophen is not a narrow therapeutic index drug. 
 
CONCLUSION 
 
According to the present regulations, acetaminophen is a BCS class III API, although 
possessing properties borderline to BCS Class I. Other workers also classified 
acetaminophen as BCS Class III.[89] The classification of Kasim et al.[21] as BCS Class IV is 
probably due to use of incorrect solubility data. 
 
Both of the current BCS Guidances allow the possibility for a biowaiver exclusively for BCS 
class I drugs.[86],[87] The permeability of acetaminophen, just below the critical value of 90% 
absorbed, formally excludes it from the present biowaiver criteria. However, extensions of the 
present requirements to BCS Class III APIs have received increasing attention.[90-93] 
 
Formulation effects giving rises to differences in the extent of absorption, i.e., to differences 
between the AUC of the test product and the AUC of the reference product, are not known 
and can be further minimized if the test product is formulated with excipients used in those 
drug products already having an MA. Comparative in vitro dissolution testing will provide even 
greater assurance of BE with respect to at least the extent of absorption. 
 
Absorption rate differences, i.e., differences between the Cmax of the test product and the 
Cmax of the reference product, cannot be ruled out. But there is some evidence that 
comparative in vitro dissolution testing is capable of detecting such rate differences. And the 
risk of differences in absorption rates between a test product and the reference product can 
be further minimized if it is assured that the test product does not contain osmotically active 
agents in large quantities, and/or agents that can modify gastric emptying rates, i.e., the test 
product contains only those excipients shown in Table 1, in amounts usually present in IR 
solid oral dosage forms. An indication of the amounts usually present in dosage forms for 
drug products with a MA in the USA can be obtained from the FDA Inactive Ingredients 
Database.[94] 
 
Lastly, even when comparative in vitro dissolution testing was to fail to detect an in vivo 
difference in rate of absorption, the consequences in terms of public health are not 
considered serious, as is evident from the MA's of existing drug products that can be 
supposed to differ in their rates of absorption. 
 
In summary, it is concluded that for IR acetaminophen solid oral dosage forms, containing 
acetaminophen as sole API, refraining from in vivo BE studies is scientifically justified, 
provided that:   the dosage form is rapidly dissolving under the conditions stated in the 
Guidances[86],[87] and  
  the test product contains only those excipients identified in Table 1, in the amounts normally 
used in IR solid oral dosage forms,[94] and  
  the test product shows dissolution profile similarity to the reference product under the 
conditions stated in the Guidances.[86],[87] It may be questioned if comparative dissolution 
testing in three different pHs as described in the present Guidance's is meaningful as 
acetaminophen remains unionized in all relevant pHs.[86],[87] However, maybe some 
excipients might cause of difference in dissolution profiles, making comparative dissolution 
testing at three different pH values not redundant.  
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Endnotes 
a In most situations Paq* (the dimensionless aqueous permeability[49]) is not rate limiting, 
i.e., the controlling resistance is . Thus, the equation could also be written as Peff = (D/R).  
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